US drugmaker Pfizer Inc (NYSE:PFE) on Monday abandoned its pursuit to buy AstraZeneca PLC, saying it does not plan to make an offer for the British drugmaker following the rejection of its final proposal last week. Pfizer Inc. (NYSE:PFE) stock performance was -0.57% in last session and finished the day at $29.49. Traded volume was…
ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) presented results from a global, multi-center, open-label, comparator-controlled phase II study in patients undergoing total knee replacement surgery or total knee arthroplasty (TKA). Two doses of ISIS-FXIRx (200mg, 300mg) were compared to Sanofi’s Lovenox (enoxaparin). ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) stock performance was 11.26% in last session and finished the day at…
One solution, developed by PTC Therapeutics Inc. (NASDAQ:PTCT), a US biotechnology company, is to intervene in the transcription process in which the DNA is converted first to messenger RNA and then into protein. PTC Therapeutics Inc. (NASDAQ:PTCT)’s experimental drug ataluren is designed to override the false stop signal by interacting with the ribosome – the…
PTC Therapeutics, Inc. (NASDAQ:PTCT) announced a corporate update and reported its financial results for the fourth quarter and full-year ended December 31, 2013. In April 2013, PTC Therapeutics, Inc. (NASDAQ:PTCT) initiated the confirmatory Phase 3 ACT DMD (Ataluren Confirmatory Trial in DMD) clinical trial evaluating ataluren as a potential treatment for patients with nonsense mutation…
Registrant and three of its wholly-owned subsidiaries, Reliv, International, Inc (NASDAQ:RELV), Reliv World Corporation and SL Technology, Inc. entered into a Credit Agreement with BMO Harris Bank N.A. (the “Bank”) pursuant to which the Bank agreed to provide certain credit facilities to Registrant, including a Term Loan in the principal amount of $3,481,961 and a…
Peregrine Pharmaceuticals (NASDAQ:PPHM) announced its earnings results on Friday. The company reported ($0.06) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.06). Peregrine Pharmaceuticals (NASDAQ:PPHM) stock performance was -8.05% in last session and finished the day at $2.40. Traded volume was 14.14million shares in the last session and the average volume…
